These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8748213)

  • 1. Endocrine abnormalities in hemodialysis patients with iron overload: reversal with iron depletion.
    el-Reshaid K; Seshadri MS; Hourani H; Qurtom M; Kamel H
    Nutrition; 1995; 11(5 Suppl):521-6. PubMed ID: 8748213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis.
    Seifert A; von Herrath D; Schaefer K
    Q J Med; 1987 Dec; 65(248):1015-24. PubMed ID: 3455553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin treatment in haemodialysis patients with iron overload.
    el-Reshaid K; Johny KV; Hakim A; Kamel H; Sebeta A; Hourani H; Kanyike FB
    Acta Haematol; 1994; 91(3):130-5. PubMed ID: 8091934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum ferritin and tissue iron in anemic dialysis patients.
    Bárány P; Eriksson LC; Hultcrantz R; Pettersson E; Bergström J
    Miner Electrolyte Metab; 1997; 23(3-6):273-6. PubMed ID: 9387132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron loading and endocrine functions in nontransfused patients with beta-thalassemia intermedia or sickle-cell thalassemia.
    Flatau E; Resnitzky P; Kauffman N; Harpaz S; Kohn D
    Isr J Med Sci; 1981 Jan; 17(1):22-7. PubMed ID: 7461943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
    Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F
    J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
    Chen YC; Hung SC; Tarng DC
    Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - a prospective cross-over study.
    Hsu PY; Lin CL; Yu CC; Chien CC; Hsiau TG; Sun TH; Huang LM; Yang CW
    J Nephrol; 2004; 17(5):693-700. PubMed ID: 15593037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring iron status in end-stage renal disease patients on hemodialysis.
    Rafi A; Karkar A; Abdelrahman M
    Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Endocrine disorders and hormonal therapy in HIV infections].
    Hofbauer LC; Heufelder AE
    Dtsch Med Wochenschr; 1997 May; 122(19):621-6. PubMed ID: 9182028
    [No Abstract]   [Full Text] [Related]  

  • 11. [Anomalies of human gonadal function in periodic hemodialysis: role of the etiology of kidney failure and the role of iron overload].
    Dueymes JM; Caron P; Pourrat JP; Louvet JP; Conté JJ
    Nephrologie; 1983; 4(2):69-74. PubMed ID: 6877481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human erythropoietin and phlebotomy in the treatment of iron overload in chronic hemodialysis patients.
    Lazarus JM; Hakim RM; Newell J
    Am J Kidney Dis; 1990 Aug; 16(2):101-8. PubMed ID: 2382644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin.
    Markowitz GS; Kahn GA; Feingold RE; Coco M; Lynn RI
    Clin Nephrol; 1997 Jul; 48(1):34-40. PubMed ID: 9247776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin.
    Aggarwal HK; Nand N; Singh S; Singh M; Hemant ; Kaushik G
    J Assoc Physicians India; 2003 Feb; 51():170-4. PubMed ID: 12725261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine complications of sarcoidosis.
    Bell NH
    Endocrinol Metab Clin North Am; 1991 Sep; 20(3):645-54. PubMed ID: 1935922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human recombinant erythropoietin and phlebotomy in the treatment of iron overload in uremic patients.
    Chen KS; Leu ML; Huang CC
    Changgeng Yi Xue Za Zhi; 1995 Sep; 18(3):248-53. PubMed ID: 8521335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis.
    Acharya VN; Sinha DK; Almeida AF; Pathare AV
    J Assoc Physicians India; 1995 Aug; 43(8):539-42. PubMed ID: 8772973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases.
    Tauchmanovà L; Selleri C; Rosa GD; Pagano L; Orio F; Lombardi G; Rotoli B; Colao A
    Cancer; 2002 Sep; 95(5):1076-84. PubMed ID: 12209694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical and economic significance of iron replacement in anemia treated with recombinant human erythropoietin in patients on hemodialysis].
    Vanková S; Safárová R; Horácková M; Herink J; Rychlík I; Bahbouh R; Půtová I
    Cas Lek Cesk; 2001 Apr; 140(7):209-13. PubMed ID: 11374225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epoetin omega for treatment of anemia in maintenance hemodialysis patients.
    Sikole A; Spasovski G; Zafirov D; Polenakovic M
    Clin Nephrol; 2002 Mar; 57(3):237-45. PubMed ID: 11924756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.